Pragmatic Randomized Controlled Study to Assess the Effectiveness of Two Patient Management Strategies in Mild to Moderate Ulcerative Colitis (OPTIMISE)

  • days left to enroll
  • participants needed
  • sponsor
    Ferring Pharmaceuticals
Updated on 24 October 2022


The purpose of this study is to provide evidence that a therapy of Ulcerative Colitis (UC) disease adjusted on tight monitoring of non-invasive parameters, such as clinical symptoms and faecal calprotectin (FC) (substance that is released when intestines are inflamed and that can be measured in faeces), can provide significantly higher benefit for the participants in terms of disease control and quality of life (QoL) improvement, compared to a symptom-based approach only.

Condition Mild-to-moderate Ulcerative Colitis
Treatment Faecal Calprotectin Home Test, PRO-2 Scoring
Clinical Study IdentifierNCT04340895
SponsorFerring Pharmaceuticals
Last Modified on24 October 2022


Yes No Not Sure

Inclusion Criteria

Adult Participants (≥ 18 years old)
Participants with active mild-to-moderate UC (with RB and bowel inflammation confirmed by endoscopy)
Participants with treatment with 5-aminosalicylic acid (5-ASA) ≤ 2.4 g/day or with no treatment regimen at Baseline
Participants who agree to use FC home test (to dose FC in faeces as a marker of inflammation)
Participants with internet access and smartphone with camera

Exclusion Criteria

Participants currently enrolled in another interventional study
Participants not willing to undergo an endoscopy at the end of study
Participants with contraindications to treatment with 5-ASA and/or 2nd generation corticosteroids
Participants not willing to perform FC self-testing in faeces at home
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note